医学
卵圆孔未闭
抗血栓
心脏病学
心理干预
心脏病
心脏瓣膜
外科
内科学
重症监护医学
阿司匹林
疾病
作者
Paolo Calabrò,Felice Gragnano,Giampaolo Niccoli,Rossella Marcucci,Marco Zimarino,Carmen Spaccarotella,Giulia Renda,Giuseppe Patti,Giuseppe Andò,Elisabetta Moscarella,Massimo Mancone,Arturo Cesaro,Gennaro Giustino,Raffaele De Caterina,Roxana Mehran,Davide Capodanno,Marco Valgimigli,Stephan Windecker,George Dangas,Ciro Indolfi,Dominick J. Angiolillo
出处
期刊:Circulation
[Ovid Technologies (Wolters Kluwer)]
日期:2021-10-19
卷期号:144 (16): 1323-1343
被引量:7
标识
DOI:10.1161/circulationaha.121.054305
摘要
Contemporary evidence supports device-based transcatheter interventions for the management of patients with structural heart disease. These procedures, which include aortic valve implantation, mitral or tricuspid valve repair/implantation, left atrial appendage occlusion, and patent foramen ovale closure, profoundly differ with respect to clinical indications and procedural aspects. Yet, patients undergoing transcatheter cardiac interventions require antithrombotic therapy before, during, or after the procedure to prevent thromboembolic events. However, these therapies are associated with an increased risk of bleeding complications. To date, challenges and controversies exist regarding balancing the risk of thrombotic and bleeding complications in these patients such that the optimal antithrombotic regimens to adopt in each specific procedure is still unclear. In this review, we summarize current evidence on antithrombotic therapies for device-based transcatheter interventions targeting structural heart disease and emphasize the importance of a tailored approach in these patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI